LifeTech Capital

LifeTech Capital is positive on Marina Biotech (NASDAQ: MRNA), and rates shares at "Strong Speculative Buy." It has a $2.50 price target on shares. In a note to clients, LifeTech writes, "Marina Biotech announced the publication of data for their DiLA2-based delivery technology for systemic...

LifeTech Capital has released a report regarding the research done by NovaBay Pharmaceuticals (AMEX: NBY) on urinary catheter blockage and encrustation. According to the report, ” NovaBay Pharmaceuticals presented a poster on the efficacy of its lead Aganocide NVC-422 the for prevention and...

LifeTech Capital is maintaining its Strong Buy rating and $4 PT on shares of NeoStem, Inc. (NYSE: NBS). “NeoStem has Record $69.8M in Revenues for 2010,” LifeTech Capital writes. “Suzhou Erye Pharmaceuticals accounted for the majority of revenues in 2010 while new business units, including the...

On April 5, 2010, Merck (NYSE: MRK) announced that they are acquiring Inspire Pharmaceuticals (NASDAQ: ISPH) for approximately $430 million, LifeTech Capital reports. “Merck stated goal is to strengthen their ophthalmic portfolio with Inspire's AZASITE (azithromycin ophthalmic solution) for the...

LifeTech Capital is out with its report today on StemCells (NASDAQ: STEM), maintaining Strong Speculative Buy. In a note sent to clients, LifeTech Capital writes, "We are maintaining a Strong Speculative Buy recommendation and Price Target of $2.20: We believe StemCells Inc. is one of the most...

LifeTech Capital maintained its Bionovo (NASDAQ: BNVI) Strong Speculative Buy rating and $7.50 price target in a research report published today. In the report, LifeTech Capital states, "Bionovo raised $27.8M in net proceeds in a financing led by Roths-Invest Asset Management AG, from the Nathan...

LifeTech Capital raised its Echo Therapeutics (OTC: ECTE) price target to $6 from $4.50 and maintained Echo Therapeutics Strong Speculative Buy rating in a research report published today. In the report, LifeTech Capital states, "Echo Therapeutics Symphony™ transdermal continuous glucose monitor (...

LifeTech Capital is out with its report on Marina Biotech (NASDAQ: MRNA), after initiating MRNA at Strong Speculative Buy. In a note to clients, LifeTech Capital writes, "We believe that Marina Biotech represents one of the potential winners in the relatively new and fragmented RNAi space. In our...